Navigation Links
Centrix Pharmaceutical Announces Clofera(TM), a Unique Antitussive and Nasal Decongestant for the Temporary Relief of Cough and Nasal Congestion
Date:8/14/2009

BIRMINGHAM, Ala., Aug. 14 /PRNewswire/ -- Centrix Pharmaceutical, Inc., a privately-held specialty pharmaceutical company focused on Pediatrics and Women's Health, announced plans to commercially launch Clofera(TM) for the temporary relief of cough and nasal congestion.

Clofera(TM) is indicated for the temporary relief of cough and nasal congestion due to the common cold, hay fever, or other upper respiratory allergies. Clofera(TM) contains a non-narcotic antitussive, chlophedianol hydrochloride, in addition to nasal decongestant, pseudoephedrine hydrochloride. The product is specifically formulated without dyes, sugar, alcohol or gluten to meet particular consumer needs and address patient sensitivities. Clofera(TM) is expected to release during the beginning of the fourth quarter.

"We are pleased to introduce Clofera to temporarily control the cough reflex, therefore reducing the intensity of coughing with a product that is free of narcotic effects. Clofera provides physicians with another therapeutic option in the management of cough and congestion associated with allergic rhinitis or the common cold. The release of Clofera further compliments our goal to develop and expand the Centrix specialty portfolio," stated John R. (Bob) Booth, President and CEO of Centrix Pharmaceutical.

About Clofera(TM)

Clofera(TM) temporarily controls the cough reflex, temporarily relieves nasal congestion, swollen nasal passages, sinus congestion and pressure. Clofera(TM) should not be used in patients taking monoamine oxidase inhibitors or with known hypersensitivity to any of the components of the product. Patients with a chronic cough, asthma, emphysema, mucus production, heart disease, high blood pressure, thyroid disease, diabetes, or enlarged prostate should consult physician before use. Recommended dosage should not be exceeded. Clofera(TM) contains no dextromethorphan, antihi
'/>"/>

SOURCE Centrix Pharmaceutical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

4

GOOD

Page: 1 2

Related medicine news :

1. CareCentrix Adds to Senior Leadership Team
2. HeartCentrix Informatics Solution from Cardiac Science Now Certified with Allscripts Electronic Health Records
3. Gentiva(R) Health Services Promotes Boelsen to Senior Vice President, CareCentrix(R)
4. Cardiac Science Announces HeartCentrix(R) ECG Informatics Connectivity With Henry Schein Medical Systems MicroMD(R) EMR 5.0
5. Cardiac Science Announces HeartCentrix(R) ECG Informatics Connectivity With Greenway(R) Medical Technologies
6. WuXi PharmaTech Selected as One of the Top Ten Employer for New College Graduates in Pharmaceutical Industry in 2009
7. Hisamitsu Pharmaceutical Announces Expiration of HSR Waiting Period for Its Proposed Acquisition of Noven Pharmaceuticals
8. Mylan Pharmaceuticals Receives Final FDA Report and Reaffirms Its 48-Year Exemplary Record of Quality
9. Thomson Reuters Invites You to the First Latin American Forum Covering the Pharmaceutical Industry
10. Sun Pharmaceutical to File HSR Application for Taro Tender Offer
11. Endo Pharmaceuticals Announces Resignation of Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... and SUNNYVALE, Calif., Dec. 15 ... Information Technology and Managed Services, and Ruckus ... (WLAN) solutions provider, today announce their partnership ... interference avoidance technology. ,, The collaboration will ... with Ruckus, cutting-edge Wi-Fi solutions, including its ...
(Date:12/15/2009)... and money with comprehensive solution , ... ... Epocrates, Inc., developer of the most popular medical application ... premium software suite for the platform – Epocrates® Essentials ... on Epocrates products on their iPhone and iPod touch devices ...
(Date:12/15/2009)... the most caring, conscientious practice you have ever been a part ... of Dallas, we can help to achieve this goal and meet ... ... 2009 -- The Dermatology Center of Dallas, a Dallas based, full-service ... Beth “J.B.” Foshee, MD in their practice. Dr. Foshee joins ...
(Date:12/15/2009)... ... (PRWEB) December 10, 2009 -- Millions of men and women suffer from ... of red, blue or purple veins that spider-web across the nose, cheeks, ... it’s been estimated that 25-30% of women and 10-20% of men suffer ... Veinwave has been available for over 8 years in Europe (where ...
(Date:12/15/2009)... Westchester, Ill. A study in the Dec. ... Sleep Medicine indicates that significant associations exist ... gastrointestinal regurgitation and headaches in young school-aged children. ... that parent-reported insomnia was 3.3 times more likely ... more likely in children with headaches. Nineteen ...
Breaking Medicine News(10 mins):Health News:Atrion Networking Corporation Selects Ruckus Wireless for 'Reliable as Wire' Enterprise Wi-Fi Service 2Health News:Atrion Networking Corporation Selects Ruckus Wireless for 'Reliable as Wire' Enterprise Wi-Fi Service 3Health News:Epocrates Expands iPhone Offerings with New Premium Content 2Health News:Epocrates Expands iPhone Offerings with New Premium Content 3Health News:Jeri Beth “J.B.” Foshee, MD Joins Dermatology Center of Dallas 2Health News:Vein Center & CosMed, Inc. Selected as Exclusive St. Louis Provider of FDA-Cleared Device 2Health News:Insomnia symptoms linked with medical complaints in young school-aged children 2Health News:Insomnia symptoms linked with medical complaints in young school-aged children 3
... broad range of imaging solutions to cardiologyORLANDO, Fla., March ... ) provides imaging excellence and workflow enhancements for cardiology ... Session of the American College of Cardiology (ACC) from ... at the Siemens booth at this year,s conference is ...
... UpSpring Baby (TM) executives, Lisa Williamson and Julie Jumonville, ... agreements with new and existing investors to raise gross ... for the innovative parent and baby products company based ... used for new product development and sales support as ...
... as treatment target against disease progression , , ... identified marker for prostate cancer progression may also ... Michigan researchers say. , Previous research has found ... linked with neoplastic progression in prostate cancer. However, ...
... Document Management with Electronic Medical Record Systems ... Meet HIPAA Regulatory RequirementsPROVO, Utah, March 25 ... of its electronic document management (EDM) ... Practice Management (PM) systems which are used by ...
... NovaLign(TM) Orthopaedics, Inc., formerly known as OsteoLign, Inc., ... and Drug Administration to market its Intramedullary Fixation System, ... treatment of long bone fractures, including the humerus, tibia ... enter the intramedullary fracture fixation market, estimated to be ...
... plan to leverage Health Integrated,s Synergy Targeted Population ... health for Medicaid subscribersPORTLAND, Ore. and TAMPA, Fla., ... that provides Medicaid and Medicare managed care services ... Population Health Management company, are partnering to improve ...
Other Medicine News:Health News:Siemens Highlights Its Ultimate Hybrid System at ACC 2009 2Health News:Siemens Highlights Its Ultimate Hybrid System at ACC 2009 3Health News:Siemens Highlights Its Ultimate Hybrid System at ACC 2009 4Health News:Siemens Highlights Its Ultimate Hybrid System at ACC 2009 5Health News:Female Entrepreneurs Secure $4M in New Financing for UpSpring Baby 2Health News:eFileCabinet Helps Medical Offices Realize Full Benefits of Electronic Medical Record Systems 2Health News:NovaLign(TM) Orthopaedics, Inc. Announces its First 510(K) Clearance From the FDA for New Intramedullary Fixation System 2Health News:CareOregon and Health Integrated Partner to Enhance Services for Oregonians with Chronic Illness 2Health News:CareOregon and Health Integrated Partner to Enhance Services for Oregonians with Chronic Illness 3
(Date:12/14/2009)... a statement by Linda A. Suydam, D.P.A., president ... today,s release of the National Institute on Drug ... released today on this year,s Monitoring the Future ... to educate and empower parents with the information ... medicine abuse. The Consumer Healthcare Products Association (CHPA) ...
(Date:12/14/2009)... board of directors of Eli Lilly and Company (NYSE: ... the first quarter of 2010 of $0.49 a share ... is payable March 10, 2010 to shareholders of record ... 12, 2010. ,, Lilly, a leading innovation-driven corporation, is ... the latest research from its own worldwide laboratories and ...
(Date:12/14/2009)... Cardinal Health today announced that executives of ... ,, Goldman Sachs CEO Unplugged Conference ... Sachs Conference Center in New York. 28th ... at Noon EST at the Westin St. Francis Hotel ... executives will discuss Cardinal Health,s diverse products and services, ...
Breaking Medicine Technology:Statement From the Consumer Healthcare Products Association(CHPA) on Annual Monitoring the Future Survey on Drug Abuse 2Statement From the Consumer Healthcare Products Association(CHPA) on Annual Monitoring the Future Survey on Drug Abuse 3Cardinal Health Executives to Speak at Two Investor Events in January 2Darwins Kim Lloyd to Speak on Panel at American Hospital Association Solutions Roundtable June 3 2009 47693 1Darwins Kim Lloyd to Speak on Panel at American Hospital Association Solutions Roundtable June 3 2009 47693 2Darwins Kim Lloyd to Speak on Panel at American Hospital Association Solutions Roundtable June 3 2009 47693 3A Little Bit of Leg Work Goes a Long Way for Travel Advantage Network and Mental Health Charity 47690 1A Little Bit of Leg Work Goes a Long Way for Travel Advantage Network and Mental Health Charity 47690 2Photos 3A Philips Expands Home Healthcare Commitment With Portable Life Support Ventilator 3B Offers Ease of Use Portability and Versatility for Pati 47687 1Photos 3A Philips Expands Home Healthcare Commitment With Portable Life Support Ventilator 3B Offers Ease of Use Portability and Versatility for Pati 47687 2Photos 3A Philips Expands Home Healthcare Commitment With Portable Life Support Ventilator 3B Offers Ease of Use Portability and Versatility for Pati 47687 3
... company,s third to enter human trials in 2 years, ... that the U.S. Food and Drug Administration has approved ... hypertension,drug. With the approval, Addrenex has launched a phase ... for hypertension., The phase 2 trial is a ...
... October 23 , - First Responses in ... key role in cell duplication and are,implicated in ... of tumour. A,lecture focusing on Aurora kinase inhibitors ... the 20th EORTC-NCI-AACR Symposium "Molecular,Targets and Cancer Therapeutics" ...
Other Medicine Technology:Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415 2Nerviano Medical Sciences Invited by EORTC-NCI-AACR to Present the State-of-the-Art of Aurora 2Nerviano Medical Sciences Invited by EORTC-NCI-AACR to Present the State-of-the-Art of Aurora 3
Angled 45 degree shafts with 10.5 mm tying and 1 mm of tip crisscross serrated. Serrated handle with dull finish. Manufactured in titanium. Overall length 3.2 inches....
Straight, 7 mm tying platform. Castroviejo handle. Manufactured in titanium. Overall length 4.2 inches....
Straight shafts with 6 mm tying platform. Wide serrated handle with polished finish. Overall length 4.3 inches. Overall length 4.3 inches....
Curved shafts and tips with 6.5 mm tying platform. Flat serrated handle with dull finish. Overall length 3.9 inches. Overall length 3.9 inches....
Medicine Products: